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Background: Supplemental melatonin may ameliorate metabolic syndrome (MetS) components, but data from
placebo-controlled trials are lacking.
Methods: We conducted a double-blind, placebo-controlled, crossover, Phase II randomized pilot clinical trial to
estimate the effects of melatonin supplementation on MetS components and the overall prevalence of MetS. We
randomized 39 subjects with MetS to receive 8.0 mg oral melatonin or matching placebo nightly for 10 weeks. After
a 6-week washout, subjects received the other treatment for 10 more weeks. We measured waist circumference,
triglycerides, HDL cholesterol, fasting glucose, and blood pressure (BP) in each subject at the beginning and end of
both 10-week treatment periods. The primary outcome was the mean 10-week change in each MetS component,
and a secondary outcome was the proportion of subjects free from MetS, after melatonin versus placebo.
Results: The mean 10-week change for most MetS components favored melatonin over placebo (except fasting
glucose): waist circumference −0.9 vs. +1.0 cm (p = 0.15); triglycerides −66.3 vs. -4.2 mg/dL (p = 0.17); HDL cholesterol −0.2
vs. -1.1 mg/dL (p = 0.59); fasting glucose +0.3 vs. -3.1 mg/dL (p = 0.29); systolic BP −2.7 vs. +4.7 mmHg (p = 0.013);
and diastolic BP −1.1 vs. +1.1 mmHg (p = 0.24). Freedom from MetS tended to be more common following
melatonin versus placebo treatment (after the first 10 weeks, 35.3% vs. 15.0%, p = 0.25; after the second 10 weeks,
45.0% vs. 23.5%, p = 0.30). Melatonin was well-tolerated.
Conclusions: Melatonin supplementation modestly improved most individual MetS components compared with
placebo, and tended to increase the proportion of subjects free from MetS after treatment.
Trial registration: NCT01038921, clinicaltrials.gov
Keywords: Melatonin, Metabolic syndrome, Randomized controlled trialBackground
The metabolic syndrome (MetS) is a cluster of metabolic
risk factors with increasing worldwide prevalence [1].
The metabolic syndrome has been strongly associated
with the risk of adverse cardiovascular events, new-onset
diabetes mellitus, and all-cause mortality [2]. Therefore,
there is great interest in identifying interventions that
can reduce the risk of adverse outcomes in persons with
MetS.
Melatonin (N-acetyl-5-methoxytryptamine) is an endogen-
ous indoleamine hormone (chemical structure C13H16N2O2)* Correspondence: pdterry@utk.edu
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unless otherwise stated.that is synthesized and secreted by the pineal gland.
Melatonin release into the circulation is augmented in
darkness and decreased during exposure to light, and
facilitates the orientation of the body’s physiologic sys-
tems according to circadian patterns [3]. Animal studies
and non-randomized human studies suggest that mela-
tonin supplementation may ameliorate components of
MetS, including elevated glucose and insulin resistance,
hypertension, dyslipidemia, and obesity [4-7]. In addition,
human genome-wide association studies suggest a link
between circadian rhythm regulation and glucose homeo-
stasis mediated through the melatonin signaling pathway
[8-10]. Studies also implicate altered plasma melatonin
rhythms in the etiology of type 2 diabetes [11] as well as
MetS [12]. Epidemiologic studies suggest an inversetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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insulin resistance [13,14]. However, randomized, placebo-
controlled trials in humans are lacking.
We conducted a pilot randomized, double-blind, cross-
over, placebo-controlled, Phase II clinical trial of mela-
tonin supplementation in 39 women and men with
MetS to determine whether melatonin is efficacious in
ameliorating the individual MetS components (plasma
glucose, blood pressure, triglycerides, waist circumfer-
ence, and HDL-cholesterol), and in increasing the pro-
portion of subjects free from MetS after treatment.
Methods
The design and rationale of this trial has been published
[15]. Screening of the first patient occurred in April 2010,
enrollment ended December 2011, and trial follow-up was
completed July 2012. The Institutional Review Board of
Emory University approved the study. This report con-
forms with the CONSORT standards for reporting of ran-
domized controlled trials [16].
Entry criteria
Eligible subjects met three or more of the following five
MetS criteria established by the National Heart, Lung,
and Blood Institute and the American Heart Association
[17]: elevated fasting glucose (≥100 mg/dL), elevated
blood pressure (>130 mmHg systolic blood pressure
[SBP] or >85 mmHg diastolic diastolic blood pressure
[DBP]), elevated triglycerides (≥150 mg/dL), reduced
HDL cholesterol (<40 mg/dL in men, <50 mg/dL in
women), and enlarged waist circumference (≥102 cm in
men, ≥88 cm in women). Subjects had to meet these cri-
teria even if on risk factor treatment. We excluded sub-
jects with diabetes because we were interested in the
effect of melatonin on MetS before diabetes had devel-
oped. We excluded subjects taking calcium channel
blockers based on data that melatonin may interact with
calcium channel blockers to increase blood pressure [18].
Recruitment, screening, and randomization
Participants were recruited from sources within Emory
Healthcare, including subjects with MetS from a prior
study funded by the National Institute of Diabetes and
Digestive Kidney; the Preventive Cardiology Clinic at
The Emory Clinic in Atlanta, GA; and advertisements
posted throughout The Emory Clinic. Screening in-
cluded a detailed chart review, in-person interviews,
physical exam, blood tests to document the presence of
MetS, and oral glucose tolerance testing to rule out dia-
betes. Individuals meeting entry criteria entered a 10-day
run-in phase to assess adherence to therapy. Those who
took at least 80% of their run-in tablets without report-
ing intolerable side effects were randomized.A total of 72 subjects were screened for eligibility
(Figure 1), of which 33 were excluded during screening
and run-in phases. For the 39 randomized subjects, an
independent biostatistician randomly generated four
permuted blocks of size 10 (five melatonin and five pla-
cebo), with which subjects were randomized to receive
either 8.0 mg oral melatonin or matching placebo daily
(one hour before bedtime) for 10 weeks. After the first
10 weeks, each subject underwent a 6-week washout
period, and then crossed over to receive the alternative
treatment for another 10-weeks (Figure 2). Study inves-
tigators, participants and their personal health care pro-
viders, and laboratory staff were blinded to treatment
assignment.
Melatonin treatment
As previously described [15], we studied a daily dose of
8.0 mg melatonin compared with placebo to be taken
one hour before bedtime. The Investigational Drug
Service at Emory University purchased melatonin in
powder form, compounded the melatonin into 8.0 mg
immediate-release melatonin in gelatinous capsules,
and also made the matching placebo capsules. A daily
dose of 8.0 mg of immediate-release melatonin was
chosen based on prior studies showing similar side ef-
fect profiles between melatonin doses as high as 7–
8 mg and placebo [19]. The duration of 10 weeks of
study treatment for each of the melatonin and placebo
treatment phases was based on human studies that
showed that two months of melatonin therapy effected
important changes in metabolic parameters including
blood pressure, glucose, and serum lipids [7].
Measurements
We first measured the five MetS components at screening
to determine study eligibility. Following randomization,
we again measured the five MetS components in each en-
rolled subject at four additional time points (Figure 2):
1) at the beginning of the first 10-week period of mela-
tonin or placebo administration; 2) at the end of the
first 10 weeks; 3) following the interval 6-week washout
period (i.e. at the start of the second 10-week period of
the crossover treatment); and 4) at the end of the sec-
ond 10-week period. We also measured 24-hour ambu-
latory blood pressure at each of the four time points
[20]. The specific assays, methods, and equipment used
to measure these MetS components have been de-
scribed [15].
Outcomes
The primary outcome was the change in each of the five
MetS components during melatonin treatment com-
pared with placebo. A secondary outcome was the pro-
portion of subjects free from MetS following melatonin
Figure 1 Study flow diagram.
Goyal et al. Diabetology & Metabolic Syndrome 2014, 6:124 Page 3 of 11
http://www.dmsjournal.com/content/6/1/124versus placebo treatment after the first 10-week period,
and again after the second 10-week period. The inci-
dence of major adverse clinical events and minor side ef-
fects were documented.
Power calculations
This Phase II trial was designed to provide estimates of
treatment effect size and variability [15]. Nonetheless, a
target sample size of 30 patients completing the trial
would result in statistical power being between 0.79 to
0.86 utilizing a two-sided Type I error rate alpha of 0.05
for the following mean within-subject differences (for
melatonin minus placebo) for each of the following MetS
components: fasting glucose, −5.5 mg/dL; systolic bloodFigure 2 Crossover study design and measurement intervals.pressure, −5.5 mmHg; HDL cholesterol, +3.6 mg/dL;
triglycerides, −7.5 mg/dL; and waist circumference, −
4.0 cm, with estimated standard deviations as previ-
ously reported [15]. We also calculated the statistical
power for the “global” test of whether melatonin would
improve at least one of the five MetS components,
based on the multivariate Hotelling T2 in PASS 2005
(Kaysville, UT), with >90% power with a two-sided
alpha of 0.05.
Statistical analysis
Analysis of the primary endpoints was performed ac-
cording to the intention-to-treat principle. Standard stat-
istical methods for a one-period crossover design were
Table 1 Baseline characteristics according to the
treatment which subjects were randomized to receive






Age, years (mean, SD) 62.7 ± 9.6 57.6 ± 10.1
Sex (N, %)
Male 9 (52.6%) 8 (40.0%)
Female 10 (47.4%) 12 (60.0%)
Race (N, %)
White 13 (68.4%) 11 (55.0%)
African-American 6 (31.6%) 7 (35.0%)
Asian 0 (0.0%) 1 (5.0%)
Hispanic/Latino 0 (0.0%) 1 (5.0%)
Waist circumference, cm (mean, SD)
Male 114.1 ± 11.1 110.4 ± 5.3
Female 102.6 ± 8.8 104.7 ± 11.4
Height, meters (mean, SD) 1.67 ± 0.11 1.70 ± 0.12
Weight, kg (mean, SD) 97.5 ± 19.4 98.1 ± 14.3
Body mass index (mean, SD) 35.2 ± 7.0 34.1 ± 6.4
HDL-cholesterol, mg/dL (mean, SD)
Male 37.7 ± 6.7 35.7 ± 6.3
Female 44.7 ± 6.7 48.5 ± 12.5
LDL-cholesterol, mg/dL (mean, SD) 115.2 ± 33.6 115.9 ± 34.1
Triglycerides, mg/dL (mean, SD) 152.0 ± 59.3 210.1 ± 227.5
Fasting glucose, mg/dL (mean, SD) 102.2 ± 14.7 103.0 ± 13.3
SBP average clinic value, mmHg (mean, SD) 125.7 ± 14.5 126.5 ± 19.4
DBP average clinic value, mmHg (mean, SD) 76.5 ± 10.9 77.7 ± 12.0
Ambulatory blood pressure readings
(mmHg)
Full 24-hour period
Measurements per subject (mean, SD) 22.7 ± 2.7 22.4 ± 2.6
Average SBP, mmHg (mean, SD) 126.4 ± 9.6 132.4 ± 9.3
Average DBP, mmHg (mean, SD) 74.2 ± 9.6 77.5 ± 9.0
Wake period (0800 to 2200)
Measurements per subject (mean, SD) 13.4 ± 2.4 13.2 ± 1.8
Average SBP, mmHg (mean, SD) 131.3 ± 10.1 135.5 ± 9.8
Average DBP, mmHg (mean, SD) 78.3 ± 7.4 80.7 ± 9.3
Sleep period (2200 to 0800)
Measurements per subject (mean, SD) 9.3 ± 1.0 9.2 ± 1.6
Average SBP, mmHg (mean, SD) 119.9 ± 9.7 127.5 ± 10.9
Average DBP, mmHg (mean, SD) 69.1 ± 7.1 72.5 ± 9.5
Subjects with each of the following
MetS components (N, %)
Waist circumference ≥102 cm (male)
or ≥88 cm (female)
19 (100.0%) 19 (95.0%)
Table 1 Baseline characteristics according to the
treatment which subjects were randomized to receive
during the first 10-week period of the crossover trial*
(Continued)
HDL cholesterol <40 mg/dL (male)
or <50 mg/dL (female)
14 (73.7%) 17 (85.0%)
Triglycerides ≥150 mg/dL 11 (57.9%) 11 (55.0%)
Fasting glucose ≥100 mg/dL 14 (73.7%) 13 (65.0%)
SBP ≥130 mmHg or DBP ≥85 mmHg 12 (63.2%) 16 (80.0%)
Number of MetS components per subject
(mean, SD)
3.68 ± 0.67 3.80 ± 0.95
Proportion of subjects with MetS at the
time of randomization (N, %)
11 (57.9%) 14 (70.0%)
Proportion with different number of
components of MetS (N, %)
0 0 (0.0%) 0 (0.0%)
1 2 (10.5%) 1 (5.0%)
2 6 (31.6%) 5 (25.0%)
3 7 (36.8%) 10 (50.0%)
4 4 (21.1%) 2 (10.0%)
5 0 (0.0%) 2 (10.0%)
*P values are not presented comparing melatonin with placebo for baseline
characteristics, because this is a crossover trial (and not a parallel group trial),
in which all 39 subjects received both melatonin and placebo (or placebo and
melatonin) in sequential order, and therefore each subject serves as his or her
own control.
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ing testing for both a carryover effect and an order effect
[21]. Only two subjects dropped out during follow-up,
which was deemed unrelated to study drug. Continuous
variables were summarized using means and standard
deviations, and counts with percentages. Two-sided P
values for the primary endpoint were calculated using a
mixed model. We performed interaction tests to deter-
mine whether the effect of treatment differed by sex or
race. Fisher’s exact test was used to analyze the propor-
tion of subjects free from MetS following melatonin ver-
sus placebo after the first and second 10-week periods
and to compare the incidence of reported adverse effects
for melatonin versus placebo.Results
Baseline characteristics
Baseline characteristics are shown in Table 1. Of the 39
randomized subjects, 19 received melatonin and 20 pla-
cebo in the first 10-week period. Although all 39 subjects
had MetS at screening, at the first post-randomization
study visit only 25 (64%) had at least three MetS compo-
nents, whereas 14 (36%) had only 1 or 2 MetS compo-
nents and, therefore, no longer had clinical MetS.
Table 2 Main results comparing the effect of melatonin with placebo on the components of the metabolic syndrome*
Parameter Melatonin Placebo P value (mixed model)
Weight, kg (mean, SD)
Sample size (pre, post) (n = 39, 38) (n = 38, 37)
Pre 97.6 ± 16.9 96.2 ± 15.7
Post 95.8 ± 15.9 96.8 ± 15.7
Change with treatment (post minus pre) −1.4 ± 4.4 −0.02 ± 1.8 0.087
BMI (mean, SD)
Sample size (pre, post) (n = 39, 38) (n = 38, 37)
Pre 34.6 ± 6.7 33.8 ± 6.0
Post 33.7 ± 6.1 34.0 ± 6.0
Change with treatment (post minus pre) −0.4 ± 1.4 −0.0 ± 0.7 0.090
Waist circumference, cm (mean, SD)
Sample size (pre, post) (n = 37, 37) (n = 38, 37)
Pre 108.8 ± 12.2 106.8 ± 10.5
Post 108.1 ± 11.3 108.0 ± 10.6
Change with treatment (post minus pre) (n = 35 Melatonin) −0.9 ± 5.9 1.0 ± 5.5 0.155
Triglycerides, mg/dL (mean, SD)
Sample size (pre, post) (n = 39, 38) (n = 38, 37)
Pre 207.2 ± 271.9 175.3 ± 172.1
Post 142.6 ± 74.1 172.4 ± 216.9
Change with treatment (post minus pre) −66.3 ± 211.8 −4.2 ± 99.6 0.166
LDL cholesterol, mg/dL (mean, SD)
Sample size (pre, post) (n = 39, 38) (n = 38, 37)
Pre 112.6 ± 32.3 112.7 ± 31.2
Post 108.5 ± 33.2 114.6 ± 35.3
Change with treatment (post minus pre) −3.7 ± 25.6 0.1 ± 25.5 0.564
HDL cholesterol, mg/dL (mean, SD)
Sample size (pre, post) (n = 39, 38) (n = 38, 37)
Pre 40.8 ± 7.6 42.5 ± 10.1
Post 40.9 ± 8.3 41.5 ± 8.3
Change with treatment (post minus pre) −0.2 ± 5.8 −1.1 ± 8.2 0.592
Fasting glucose, mg/dL (mean, SD)
Sample size (pre, post) (n = 39, 37) (n = 38, 37)
Pre 103.4 ± 16.5 104.6 ± 13.7
Post 102.9 ± 17.1 101.9 ± 10.2
Change with treatment (post minus pre) 0.3 ± 13.6 −3.1 ± 11.0 0.287
SBP average clinic value, mmHg (mean, SD)
Sample size (pre, post) (n = 39, 38) (n = 38, 37)
Pre 126.8 ± 16.3 122.3 ± 17.3
Post 123.4 ± 15.2 127.0 ± 15.1
Change with treatment (post minus pre) −2.7 ± 11.3 4.7 ± 13.8 0.013
DBP average clinic value, mmHg (mean, SD)
Sample size (pre, post) (n = 39, 38) (n = 38, 37)
Pre 76.6 ± 11.3 75.3 ± 10.3
Post 75.0 ± 10.8 76.4 ± 10.0
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Table 2 Main results comparing the effect of melatonin with placebo on the components of the metabolic syndrome*
(Continued)
Change with treatment (post minus pre) −1.1 ± 6.9 1.1 ± 7.4 0.243
Ambulatory BP readings
Full 24-hour period
Average SBP, mmHg (mean, SD)
Sample size (pre, post) (n = 37, 38) (n = 38, 37)
Pre 131.6 ± 11.6 130.4 ± 9.5
Post 129.6 ± 12.0 130.9 ± 12.0
Change with treatment (post minus pre) (n = 36 Melatonin) −1.4 ± 8.1 0.3 ± 8.5 0.475
Average DBP, mmHg (mean, SD)
Sample size (pre, post) (n = 37, 38) (n = 38, 37)
Pre 76.9 ± 9.0 76.3 ± 8.2
Post 75.7 ± 8.6 76.8 ± 8.3
Change with treatment (post minus pre) (n = 36 Melatonin) −1.0 ± 6.3 0.4 ± 5.7 0.409
Wake period (0800 to 2200)
Average SBP, mmHg (mean, SD)
Sample size (pre, post) (n = 37, 38) (n = 38, 37)
Pre 136.1 ± 12.4 134.2 ± 9.3
Post 133.2 ± 12.2 135.8 ± 12.6
Change with treatment (post minus pre) (n = 36 Melatonin) −2.2 ± 9.1 1.4 ± 10.5 0.169
Average DBP, mmHg (mean, SD)
Sample size (pre, post) (n = 37, 38) (n = 38, 37)
Pre 81.0 ± 9.6 79.8 ± 8.0
Post 78.9 ± 9.1 81.6 ± 8.7
Change with treatment (post minus pre) (n = 36 Melatonin) −1.8 ± 7.3 1.8 ± 6.6 0.044
Sleep period (2200 to 0800)
Average SBP, mmHg (mean, SD)
Sample size (pre, post) (n = 37, 36) (n = 38, 37)
Pre 125.8 ± 12.3 125.1 ± 11.5
Post 124.9 ± 13.4 123.9 ± 13.5
Change with treatment (post minus pre) (n = 34 Melatonin) −1.1 ± 9.0 −1.4 ± 8.9 0.807
Average DBP, mmHg (mean, SD)
Sample size (pre, post) (n = 37, 36) (n = 38, 37)
Pre 71.7 ± 9.1 71.2 ± 9.5
Post 70.7 ± 8.8 69.9 ± 8.7
Change with treatment (post minus pre) (n = 34 Melatonin) −0.7 ± 6.5 −1.3 ± 6.7 0.729
*The mean values in the “Change with treatment (post minus pre)” rows may not equal exactly the difference between the above corresponding “pre” and “post”
rows because of different sample sizes due to subject drop out in the post- versus the pre-period.
DBP = diastolic blood pressure; SBP = systolic blood pressure; SD = standard deviation.
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component with treatment
Table 2 and Figure 3 present the change before and after
melatonin versus placebo treatment for each MetS com-
ponent. Melatonin was associated with a modest reduc-
tion in mean waist circumference (−0.9 cm) compared
with a modest increase for placebo (+1.0 cm; p = 0.15).
Melatonin was associated with a mean decrease of66 mg/dL in triglycerides, compared with a 4 mg/dL de-
crease with placebo (p = 0.166). For HDL cholesterol,
both melatonin and placebo were associated with very
small reductions (−0.2 mg/dL and −1.1 mg/dL respect-
ively, p = 0.59). For fasting glucose, melatonin was asso-
ciated with a 0.3 mg/dL increase, compared with a
3.1 mg/dL reduction for placebo (p = 0.29). Mean clinic
SBP dropped by 2.7 mmHg for melatonin, compared
P = 0.155 P = 0.166 P = 0.592 P = 0.287 P = 0.013 *                      P = 0.243
*  Comparison is statistically significant at an alpha of 0.05    
DBP = diastolic blood pressure; FPG = fasting plasma glucose; M = melatonin; P = placebo; SBP = systolic blood pressure
Figure 3 Change in metabolic syndrome criteria with melatonin versus placebo treatment. The change value for each treatment was
calculated by subtracting the baseline value from the follow-up value at the end of the 10-week treatment period. Mixed model P values are
presented (as described in the text).
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clinic DBP dropped by 1.1 mmHg for melatonin versus a
1.1 mmHg increase for placebo (p = 0.24). Ambulatory
SBP dropped slightly for melatonin (−1.4 mmHg) and
increased with placebo (+0.3 mmHg, p > 0.4), and ambu-
latory DBP dropped slightly for melatonin (−1.0 mmHg)
and increased with placebo (+0.4 mmHg, p > 0.4). When
ambulatory blood pressure readings were stratified into
wake periods (0800 to 2200) and sleeping periods (2200
to 0800), melatonin reduced the wake average SBP by
2.2 mmHg (versus a 1.4 mmHg increase with placebo,
p =0.169), and reduced the average DBP by 1.8 mmHg
(versus a 1.8 mmHg increase with placebo, p = 0.044).
In contrast, melatonin did not improve SBP or DBP
compared with placebo during the sleeping periods
(Table 2).
Secondary endpoint: freedom from MetS after study
treatment
Of the 39 randomized subjects, 37 completed measure-
ments of all five MetS components at all four study
measurement periods (before and after the first and sec-
ond 10-week periods). After the first 10-week period, 6
of 17 (35.3%) of subjects taking melatonin compared
with 3 of 20 (15.0%) of those taking placebo were free
from MetS (p = 0.25). After the second 10-week period,9 of 20 (45.0%) taking melatonin compared with 4 of 17
(23.5%) taking placebo were free from MetS (p = 0.30).
Adverse effects, clinical events, and adherence
There were no differences in the reported incidence of
these side effects between treatments (Table 3). One
subject experienced an acute stroke 10 days after being
randomized to melatonin, which was determined to be
unlikely due to study drug. The subject completed the
study without any other major vascular events. The pro-
portions of subjects adherent to study drug (defined as
taking at least 80% of dispensed tablets) was 29 of 33
(87.9%) for melatonin, compared with 25 of 34 (73.5%)
for placebo (p = 0.22). Adherence for study drug tended
to decline from the first 10-week period (30 of 34, or
88.2% adherent) to the second 10-week period (24 of 33,
or 72.7% adherent, p = 0.13).
Blinding, carry over effect, order effect
Patients were able to guess correctly more often than in-
correctly which treatment (melatonin or placebo) they
were randomized to receive first. Of 37 subjects com-
pleting the final visit, 20 (54.1%) correctly guessed their
treatment assignment, 8 (21.6%) guessed incorrectly, and
9 (24.3%) documented not knowing (p = 0.053). For each
of the five MetS components, there was no detectable
Table 3 Safety, tolerability, and adverse effects of
melatonin and placebo





Pre 2/39 (5.1%) 3/38 (7.9%) 0.675
Post 3/38 (7.9%) 4/36 (11.1%) 0.707
Dizziness, patients reporting
"Yes" (N, %)
Pre 8/39 (20.5%) 8/38 (21.1%) 1.00
Post 8/38 (21.1%) 10/35 (28.6%) 0.588
Fatigue, patients reporting
"Yes" (N, %)
Pre 20/39 (51.3%) 15/38 (39.5%) 0.363
Post 23/38 (60.5%) 19/36 (52.8%) 0.639
Drowsiness, patients reporting
"Yes" (N, %)
Pre 22/39 (56.4%) 18/37 (48.6%) 0.646
Post 22/37 (59.5%) 17/36 (47.2%) 0.352
Early morning awakening or
sleep disturbances, patients
reporting "Yes" (N, %)
Pre 19/39 (48.7%) 22/37 (59.5%) 0.368
Post 22/37 (59.5%) 23/36 (63.9%) 0.811
Table 4 Results of melatonin versus placebo on clinic blood
pressure, stratified by African-American or white race
Parameter Melatonin Placebo P value
(mixed model)
SBP average clinic value,
mmHg (mean, SD)
(n = 39, 38) (n = 38, 37)
Whites (n = 22)
Pre 123.2 ± 12.7 121.4 ± 11.4
Post 119.4 ± 10.9 122.9 ± 12.4
Change with treatment
(post minus pre)
−2.6 ± 11.0 1.7 ± 12.0 0.196
African-Americans (n = 13)
Pre 131.0 ± 21.0 119.1 ± 22.1
Post 127.1 ± 18.4 131.6 ± 18.0
Change with treatment
(post minus pre)
−3.9 ± 10.9 12.5 ± 13.7 0.003
DBP average clinic value,
mmHg (mean, SD)
(n = 39, 38) (n = 38, 37)
Whites (n = 22)
Pre 73.3 ± 8.4 73.1 ± 5.9
Post 71.1 ± 5.6 72.9 ± 6.3
Change with treatment
(post minus pre)
−1.3 ± 7.2 0.0 ± 5.0 0.840
African-Americans (n = 13)
Pre 80.7 ± 14.2 76.2 ± 13.7
Post 79.3 ± 14.4 81.1 ± 13.3
Change with treatment
(post minus pre)
−1.4 ± 6.6 4.9 ± 8.6 0.034
DBP = diastolic blood pressure; SBP = systolic blood pressure;
SD = standard deviation.
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(p >0.05 in all cases).
Differences by sex and race
There were no significant interactions by sex (all p
values >0.10). For race, however, interaction P values for
clinic SBP (p =0.025) and clinic DBP (p =0.045) were
statistically significant. Accordingly, we stratified the re-
sults by race (Table 4). Among white participants, mean
SBP and DBP fell modestly with melatonin (−2.6 mmHg
and −1.3 mmHg respectively), and mean SBP increased
with placebo (+1.7 mmHg) with no change in DBP.
Among African-Americans, mean SBP and DBP also fell
modestly with melatonin (−3.9 mmHg and −1.4 mmHg
respectively), but there was a greater increase in SBP
and DBP with placebo (+12.5 mmHg and +4.9 mmHg
respectively).
Discussion
In this Phase II crossover trial, treatment with melatonin
compared with placebo was associated with modest im-
provements in most individual MetS components, as
well as a tendency towards more subjects being free
from MetS. Tolerability and adherence were comparable
between melatonin and placebo throughout the study.
We found no evidence of any order effect or carryovereffect, suggesting that the crossover design and the order
of study treatments did not discernibly bias our results.
Prior trials have been conducted to assess the impact
of melatonin on one or more MetS factors. Most of
these studies evaluated the effect of melatonin on blood
pressure, and demonstrated a reduction in blood pres-
sure associated with melatonin treatment [22-29]. Our
trial similarly demonstrated an improvement in SBP as-
sociated with melatonin versus placebo. Based on 24-
hour ambulatory blood pressure data, the change in
blood pressure following melatonin versus placebo treat-
ment was more pronounced during the awake period
(0800 to 2200) compared with the sleeping period (2200
to 0800). However, another trial reported that melatonin
lowered blood pressure at night but raised it during the
daytime compared with placebo [30]. Our trial also
found that melatonin was associated with a modest im-
provement in HDL cholesterol and triglyceride levels.
Prior melatonin trials have shown conflicting results,
with some reporting improved lipid profiles [31,32]; some
reporting worsened triglycerides [33,34]; and others
reporting no effect [35,36]. Our study found melatonin to
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fasting plasma glucose compared with placebo. Our find-
ings contrast those of prior genome-wide association stud-
ies implicating the melatonin signaling pathway and
glucose homeostasis [8-10], as well as epidemiologic stud-
ies that suggest an inverse relationship between nocturnal
melatonin secretion and insulin resistance [13,14]. How-
ever, similar to our study, other trials have also shown that
supplemental melatonin may impair glucose tolerance
[37], or have a neutral effect [35]. These discrepancies
may be due, at least in part, to differences in the tested
doses of melatonin (ranging from 0.3 to 10.0 mg daily in
prior studies) and/or in the use of controlled-release versus
fast-release melatonin [38], and suggest that relationships
between supplemental melatonin, measures of endogenous
melatonin levels, and MetS parameters are complex.
Unlike prior studies, our trial prospectively measured
all five MetS components before and after melatonin
and placebo treatment, instead of focusing on only one
or two MetS components. This is a strength of our trial,
given that the metabolic risk factors that comprise MetS
tend to cluster. Our trial showed that melatonin tended
to increase the proportion of subjects free from MetS
compared with placebo. Even though our study was not
powered to provide definitive conclusions for this end-
point, it suggests that melatonin’s modest benefits on
multiple individual MetS components may be additive
and sufficient enough to reverse the diagnosis of MetS
in some cases.
In our study, there was a race interaction for clinic
SBP and DBP, such that melatonin produced appreciably
greater improvements in SBP and DBP in African-
American participants. We consider these findings in
light of prior reports that shift work is associated with
hypertension more often in African-Americans than in
whites [39], and that African-Americans may have more
blunted circadian declines in nocturnal blood pressure
[40,41]. These racial differences in circadian blood pres-
sure variability provide a plausible explanation for mela-
tonin’s greater efficacy in African-Americans compared
with white participants in our trial.
Our trial has several limitations. First, it was designed
as a pilot study to determine the effect of melatonin
compared with placebo on individual MetS components;
it was not powered to determine whether melatonin
could increase the proportion of subjects free from MetS
following melatonin versus placebo (even though we re-
ported this as a secondary endpoint). Second, the cross-
over study design enabled each subject to serve as his or
her own control and provided greater statistical power
for a given sample size. However, because each subject
received both melatonin and placebo at different pe-
riods, subjects were able to guess which study treatment
they were randomized to receive first more often thanexpected by chance, potentially compromising blinding
to study drug. It is possible that changes in sleep pat-
terns or sides effects of melatonin were responsible for
being able to guess treatment received, even though
there were no differences in the reported rate of sleep
disturbances or other adverse effects during the trial
(Table 3). It is unlikely that participants’ suspicion re-
garding which therapy they received first affected the
primary endpoint (i.e. objective measures of MetS param-
eters), particularly since we demonstrated no carryover or
order effect in the trial. Third, separate measurements for
MetS criteria at study screening and again following
randomization were required to ensure a comparable as-
sessment of study drug efficacy during the first and second
10-week period in this crossover trial, which resulted in
14 of 39 patients (36%) no longer having three or more
MetS components after randomization. This was likely due
to regression to the mean of individual MetS components.
Conclusions
In this Phase II crossover trial of subjects with MetS,
oral melatonin produced modest improvements in most
MetS components, and also tended to increase the pro-
portion of subjects free from MetS compared with pla-
cebo. Melatonin was well-tolerated and adherence to
study drug was high. These findings support the conduct
of a subsequent, larger, parallel-group trial of MetS sub-
jects to determine whether melatonin is more efficacious
than placebo at treating MetS, as well as its downstream
cardiovascular and metabolic complications.
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